Guide: Essential Principles & Practices for GPP Compliance: Engaging stakeholders in biomedical research during the era of COVID-19by Mesh Editorial Team
This tool from AVAC in intended to help guide stakeholder engagement in COVID-19 research. Built from the Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials (GPP), it responds to needs expressed by both researchers and advocates.
This paper, published in January 2021 in Frontiers in Public Health, delves into stigma associated with the COVID-19 pandemic among different social groups in the Indian society and the mounting cases of prejudice based on race, class, and religion. It also presents insights into the varied manifestations, and the deleterious consequences of COVID-19 inspired othering brought to its potential targets in India.
U.S-based non-profit AVAC, is offering a useful set of webinars and resources looking at how rapid COVID-19 research can benefit from the lessons learned in the fight against HIV - including the importance of applying good participatory practice guidelines to ensure research is effective and inclusive
The Good Participatory Practice (GPP) Online Training Course is a four-month, hands-on eLearning experience that brings the GPP Guidelines to life through interactive online content, case studies, work assignments and online discussions.
This toolbox was developed for the World Health Organisation COVID-19 Research Roadmap and shares information on establishing and working with different types of Community Advisory Boards/Groups (CAB/Gs) in the context of COVID-19 clinical studies.
This tool, developed by the site staff of the Microbicide Development Program in Tanzania, can be used to help community, trial participants, or staff members, prioritize issues and concerns central to the trial. This tool can serve as a platform to generate a list of potential issues and provide direction for what or which issues should take priority at the research site.
Using this tool, participants can raise and explore issues they perceive as priorities in HIV prevention research; discovering links between them. An interactive and fun way for community members and participants to be involved with the planning of HIV prevention research at the site.
GPP Strengths and Gaps is a facilitator’s guide for an exercise that is designed to help evaluate GPP implementation at a site level. It can be used with community and trial participants to garner honest feedback and constructive suggestions for improvements.
The AVAC Stakeholder Interview Questions is a tool that is designed for trial site staff. It guides members of the research team through the process of conducting a one-on-one interview with a stakeholder. The tool provides guidance for talking with many different types of stakeholders. It can be used to evaluate the impact of stakeholder engagement efforts.
The GPP Trial Site Binder is a companion tool to the Good Participatory Practice guidelines that research teams can use to help develop, organize and document the stakeholder engagement activity at the site. The binder is is divided into sixteen sections aligned with the guidelines. Each section contains key steps to help research staff follow the practices, templates for documenting and planning activities, and a place to file draft documents.
The GPP Blueprint is a companion to the Good Participatory Practice guidelines for biomedical HIV prevention research. It is a step-by-step guide designed for the research team members in charge of stakeholder engagement. It presents questions, worksheets and explanations that can guide and generate a stakeholder engagement plan for a specific trial or research program.
Although Ebola-related stigmatization continues to undermine efforts to re-integrate survivors, few studies have examined what influences such stigmatizing attitudes. This paper explores the effects of both individual- and community-level factors on Ebola-related stigma in Ghana.
Published Literature: Rumours, Riots and the rejection of mass drug administration for the treatment of schistosomiasis in Morogoro, Tanzaniaby Julie Hastings, Mesh Editorial Team
This article from 2016 in the Journal of Biosocial Science outlines the case of a mass drug administration programme in Tanzania which had to be suspened after community riots
Guide: WHO Addressing violence against children, women and older people during the covid-19 pandemic: Key actionsby World Health Organisation, Mesh Editorial Team
Several countries affected by COVID-19, have seen increases in levels of violence occurring in the home, including violence against children, intimate partner violence and violence against older people. This WHO brief dated 18 June 2020, compiles key actions that the health sector can undertake within a multisectoral response to prevent or mitigate interpersonal violence based on existing WHO guidance.
The considerations presented in this document have been developed by the WHO Department of Mental Health and Substance Use as a series of messages that can be used in communications to support mental and psychosocial well-being in different target groups during the COVID-19 pandemic
This project from Médecins Sans Frontières (MSF) is developing a toolkit for MSF teams to harness social and digital technologies to better reach vulnerable displaced populations that face barriers in accessing health care. This toolkit is focussed on healthcare but will have useful insights for community engagement with health research.
This short guide is designed to assist development and humanitarian agencies to think through how risk communication and community engagement activity related to Covid-19 can be carried out without face-to-face interaction with communities. Download the guide in Bangla or English
Guide: Involving Communities - MSF Guidance document for approaching and cooperating with communitiesby Médecins Sans Frontières, Mesh Editorial Team
This guidance document is based on the joint work of the Vienna Evaluation Unit and MSF OCBA and discusses community-based approaches to medical anthropology and qualitative research
AVAC has developed a large set of supplementary tools to help research teams and other stakeholders understand, implement, and monitor the GPP guidelines. The monitoring and evaluation tools consist of a set of data collection tools for community and stakeholder engagement activities.
AVAC has developed a large set of supplementary tools to help research teams and other stakeholders understand, implement, and monitor the GPP guidelines. The GPP training tools can be used by anyone who wishes to conduct a training or to provide an overview of the GPP guidelines to a secondary audience.
WHO's COVID-19 Global Risk Communication and Community Engagement Strategy, December 2020 - May 2021 is underpinned by a socio-behavioural trends analysis and builds on the learnings from the response to-date. The shift presented in the document is towards the community engagement and participatory approaches that have been proven to help control and eliminate outbreaks in the past.
The COVID-19 Communication Network is a reliable site for social and behavior change (SBC) professionals, and other responders in need, to access and share high quality communication materials, tools and resources from global partners to address the COVID-19/Coronavirus pandemic.
Comminit.com aims to convene the communication and media development, social and behavioural change community for more effective local, national, and international development action. They have a dedicated COVID-19 hub with shared materials and knowledge
The Red Cross and Red Crescent Movement has developed a hub to share our information, knowledge and resources about community engagement and accountability. Their COVID-19 area provides tools and resources to help incorporate community engagement and accountability into COVID-19 humanitarian operations
The Compass is a curated collection of social and behavior change (SBC) resources. This special Trending Topic of SBC resources contains links to a vast array of data, infographics and guidance on topics such as risk communication, rumours and misinformation and stigma.
Guide: Empowering meaningful community engagement and involvement in global health research - critical reflections and guiding questionsby Erica Nelson, NIHR
This learning resource, from the UK's NIHR published in collaboration with the Institute of Development Studies, offers a brief set of reflections to help guide decision-making within the context of collaborative research approaches. It was published in March 2021 reflecting on the COVID-19 pandemic.
Published Literature: How can community engagement in health research be strengthened for infectious disease outbreaks in Sub-Saharan Africa? A scoping review of the literatureby Mesh Editorial Team
This literature review, published in 2021 and funded by ALERRT, looks at the body of knowledge that has been developed for community engagement specifically as it applies to emerging infectious disease outbreaks in Sub-Saharan Africa.
SSHAP (the Social Science in Humanitarian Action Platform) is a programme of work focusing on the social dimensions of emergency responses. Their site has an excellent resource page with COVID-19 as a search topic
The Stakeholder Engagement Toolkit for HIV Prevention Trials, developed by FHI360, is a guide to engaging a wide range of key stakeholders throughout the trial lifecycle.
This interactive Mesh learning webinar held in September 2020 explored the possibilities for community engagement with health research when we cannot meet in person. Find the recording here
This article analyses media coverage and public communications over the time of the Ebola outbreak in West Africa 2013-2016 with a focus on the interations between scientifically grounded information and messages from cultural and religious actors.
This user friendly set of quantitative and qualitative monitoring and evaluation tools allows users to capture, collate and analyze Community and Stakeholder Engagement (CSE) data at the clinical trial site-level. The database is designed to support engagement teams working on clinical trials on a daily, monthly, quarterly and biannual basis.